Heartflow (HTFL) vs SOPHiA GENETICS SA (SOPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SOPHiA GENETICS SA (SOPH) has outperformed Heartflow (HTFL) over the past year, gaining 71.9% versus a gain of 41.1%. Heartflow is the larger company by market cap ($4.29 billion vs $608.7 million), about 7.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HTFL | SOPH |
|---|---|---|
| Share price | $49.36 | $7.15 |
| Market cap | $4.29B | $608.66M |
| 1-day change | -2.62% | -3.12% |
| YTD return | +69.33% | +53.10% |
| 1-year return | +41.07% | +71.88% |
| 5-year return | — | -55.59% |
| EPS (TTM) | $-0.24 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.03M | — |
| Revenue growth (YoY) | +39.92% | — |
| Net income (latest FY) | $-116.79M | — |
| Gross margin | 76.80% | — |
| Operating margin | -36.39% | — |
| Net margin | -66.35% | — |
| 52-week high | $54.32 | $8.98 |
| 52-week low | $20.13 | $3.75 |
| Distance from 52-week high | -9.13% | -20.38% |
| Analyst consensus | none | none |
| Avg. price target upside | -6.81% | +36.36% |
| Average volume | 1.79M | 547.82K |
| Shares outstanding | 86.95M | 85.13M |
| Employees | 843 | 415 |
| Sector | Health Care | Technology |
| Industry | Medical/Dental Instruments | EDP Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Heartflow is about 7.1 times larger than SOPHiA GENETICS SA by market value ($4.29B vs $608.66M).
- SOPH has outperformed HTFL by 30.8 percentage points over the past year.
- The two companies sit in different sectors: Heartflow in Health Care and SOPHiA GENETICS SA in Technology.
About Heartflow
HTFL stock →HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries.
Health Care · Medical/Dental Instruments · 843 employees
About SOPHiA GENETICS SA
SOPH stock →SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Technology · EDP Services · 415 employees
HTFL vs SOPH FAQ
Which is bigger, Heartflow or SOPHiA GENETICS SA?
Heartflow (HTFL) is larger, with a market capitalization of $4.29B compared with $608.66M for SOPHiA GENETICS SA (SOPH).
Which stock has performed better over the past year, HTFL or SOPH?
SOPH returned +71.88% over the past 12 months, compared with +41.07% for HTFL (price return, excluding dividends). Past performance does not predict future results.
Are Heartflow and SOPHiA GENETICS SA in the same industry?
No. Heartflow is in the Health Care sector, while SOPHiA GENETICS SA is in Technology.